Airway Therapeutics Closes $50 Million Equity Round to Advance Late-Stage Development of Zelpultide Alfa

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Airway-Therapeutics

More Like This

PR Newswire associated0

Airway Therapeutics Receives European Medicines Agency Pediatric Committee Approval for Zelpultide Alfa's Study Plan in Bronchopulmonary Dysplasia for Very Preterm Infants

Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpultide Alfa for Preterm Neonates at Risk of Bronchopulmonary Dysplasia

Airway Therapeutics Wins 2024 ATS Whitsett Award for Abstract of Positive Phase 1b Results of Zelpultide Alfa in Preterm Neonates at Risk of Bronchopulmonary Dysplasia

PR Newswire associated0

Airway Therapeutics Appoints Biopharma Leader Joe Todisco to Board of Directors

ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine

PR Newswire associated0

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model

ACCESS Newswire associated0

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease